阿托伐他汀对急性冠脉综合征患者白细胞介素6和肿瘤坏死因子的影响

目的 探讨阿托伐他汀对急性冠脉综合征（ACS）患者血清白细胞介素6（IL-6）及肿瘤坏死因子α（TNF-α）水平变化的影响。方法将ACS患者48例随机分为阿托伐他汀组25例和常规治疗组23例，分别于治疗前及治疗4周后采用放射免疫分析方法行血清IL-6及TNF—α检测。结果ACS患者治疗前血清IL-6、TNF-α水平均明显高于对照组（均P〈0．01）。阿托伐他汀组治疗后血清IL-6（0．67±0．05）μg/L、TNF-μ（65．1±13．2）μg／L水平均明显低于治疗前，但仍高于对照组（均P〈0．05）。常规治疗组患者治疗后血清IL-6（0．74±0．08）μg／L、TNF—±（73．6±12．0）μg／L降低不明显（P〉0．05）。结论IL-6、TNF-α水平升高与ACS发病密切相关，阿托伐他汀可降低ACS患者血IL-6、TNF—α水平，具有减轻病变部位炎性反应和保护内皮细胞的作用。

Effects of atorvastatin serum levels of interleukin-6 and tumor necrosis factor-alpha in patients with acute coronary syndromes

Objective To study the effect of atorvastatin on the serum levels of intedeukin-6(IL-6)and tumor necrosis factor-alpha(TNF-α)in patients with acute coronary syndromes(ACS),so as to find out the correlation between the changes of IL-6 and TNF-α levels and ACS.Methods 48 ACS patiems who were in accordance with the inclusion criteria.Were randomly divided into atorvastatin group(n=25)and routine treatment group(n=23).The serum levels of IL-6 and TNF-α were measured with radioimmunoassay before and three weeks after treatment respectively.20 healthy physical examines in the same hospitals at the same period were taken as controls.Who did not take any medicine within the two weeks before blood sampling and their serum levels of IL-6 and TNF-α were detectod during physical examination.Results The serum levels of IL.6 and INF-α were obviously higher in the ACS patients than in the control group(P＜0.05).The serum levels of IL-6 and TNF-α in the atorvastatin group after treatment were markedly lower than those before treatment(P＜0.05)which were still higher than those in the comrol group(P＜0.05).There were no obvious changes of the serum IL-6 and INF-α levels in the routine treatment group (P＞0.05).Conclusion The higher the levels of IL-6 and TNF-α the greater the occurrence rate of ACS.Atorvastatin Can reduce the srtum levels of IL-6 and TNF-α in ACS patients,and it has the effects of inhibiting the inflammarion of the site of lesion and improving the endothelial function.